How many active ingredients of the essence applied on the face can really penetrate the barrier and penetrate into the bottom of the skin? This is the core pain point that has long been difficult to solve in the efficacy skincare and light medical beauty industries.

Industry data shows that less than 20% of active ingredients in ordinary topical skincare products can penetrate the stratum corneum to reach the active epidermis, and there are even fewer effective ingredients that can break through barriers to reach the dermis and produce real skincare effects. Peptides, with their high specificity, high safety, and strong formula adaptability, have become the core bioactive materials in the anti-aging and whitening track. However, they naturally have three major transdermal shortcomings: they are easily decomposed by surface proteases, most effective peptides are hydrophobic and insoluble, and their molecular size is difficult to penetrate the "brick wall structure" of the stratum corneum. Under the traditional application mode, even if high concentrations of peptides are added to the product, most of them only stay on the surface of the skin, ultimately becoming a mere "surface skincare" and greatly reducing the efficiency of skincare.

Nowadays, the competition logic in the peptide field has already iterated: in the first half of the industry, there is competition for peptide sequence innovation, and in the second half, there is competition for transdermal delivery technology. To break free from the limitations of superficial skincare, a complete and practical peptide transdermal solution is the key to determining product efficacy.